# A Study of TQB3455 Tablets in Subjects With Advanced Malignancies

> **NCT04340427** · PHASE1 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 50 (estimated)

## Conditions studied

- Advanced Malignancies

## Interventions

- **DRUG:** TQB3455

## Key facts

- **NCT ID:** NCT04340427
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-10
- **Primary completion:** 2021-06-30
- **Final completion:** 2021-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04340427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04340427, "A Study of TQB3455 Tablets in Subjects With Advanced Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04340427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*